Amazon and Valentino File Joint Lawsuit Against New York-Based Counterfeiter
18.6.2020 17:00:00 EEST | Business Wire | Press release
Amazon.com, Inc. (NASDAQ: AMZN) and Maison Valentino Italian luxury brand, today announced a joint lawsuit against Buffalo, New York-based Kaitlyn Pan Group, LLC and New York resident Hao Pan for counterfeiting Valentino’s iconic Valentino Garavani Rockstud shoes, and offering the infringing products for sale on https://kaitlynpanshoes.com/ and Amazon.com, in violation of Amazon’s policies and Valentino’s intellectual property rights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005160/en/
Amazon Company Statement:
“The vast majority of sellers in our store are honest entrepreneurs but we do not hesitate to take aggressive action to protect customers, brands, and our store from counterfeiters. Amazon and Valentino are holding this company accountable in a court of law and we appreciate Valentino’s collaboration throughout this investigation,” said Dharmesh Mehta, vice president, Customer Trust and Partner Support.
Valentino Company Statement:
“The Maison Valentino is one of the main protagonists of International fashion and plays a major role in the luxury division by sustaining Made in Italy. The brand represents in the global market, one of the Italian excellences in the execution of the industrial process in Italy and of the artisanal and handmade workmanship that are entirely produced in the historic Atelier of Piazza Mignanelli in Rome. We consider Made in Italy to be a fundamental value to be fully endorsed, respected and at the forefront of our business and creations. Valentino is an Italian brand operating globally and is a mirror of society. One of our core missions is to safeguard our brand and protect the Valentino Community by celebrating inclusivity and with creativity at the heart of everything we do. We feel this connection with Amazon will highlight the importance also in fashion for greater awareness, knowledge and understanding by shielding the brand online and its resources.”
Amazon shut down Kaitlyn Pan’s seller account in September 2019. Despite multiple notices of infringement and a cease and desist order, Kaitlyn Pan continues to import, distribute, sell, and offer infringing products on https://kaitlynpanshoes.com/. Kaitlyn Pan further attempted to apply for a US trademark for its infringing Valentino Garavani Rockstud shoes, flagrantly and willfully disregarding Valentino’s intellectual property.
Valentino implemented a Customs Surveillance System and enforced its Intellectual Property Rights specifically in the US. Thanks to the ongoing cooperation with US custom authorities, Valentino – in the past 3 years – seized more than 2,000 counterfeit products. Alongside with Customs enforcement, Valentino implemented a surveillance system aimed to detect counterfeit products on sale in the US market. With the help of US based local agents, Valentino has taken legal action against several companies selling both online and offline products bearing without authorization trademarks and industrial designs owned by Valentino. Valentino also carried out Online Brand Protection activity on online platforms, which led the company to remove more than 7,000 listings on several marketplaces, more than 360 websites and over 1,000 social media accounts selling counterfeit products bearing without authorization trademarks and industrial designs owned by Valentino.
This joint lawsuit builds on Amazon’s history of collaborating with brands to hold counterfeiters accountable. In line with Amazon’s past joint litigation, Valentino will receive any proceeds from this suit. Amazon strictly prohibits counterfeit products and, in 2019 alone, invested more than $500 million and had more than 8,000 employees protecting its store from fraud and abuse, including counterfeiting and IP infringing products. As a result of its efforts, 99.9% of all products viewed by customers on Amazon have not received a valid counterfeit complaint. Amazon also works closely with law enforcement agencies and reports all confirmed counterfeiters to US and European authorities to help them build stronger criminal cases.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
About Valentino
The House of Valentino based in Italy expresses a point of view on the contemporary world using history as a playground and the Atelier in the heart of Rome, the Eternal City, as a place that produces both beauty and thought. The story began in 1959. The year 2016 marks a new beginning, under the Creative Direction of Pierpaolo Piccioli. A new set of values, that are both of the moment and faithful to its heritage, are created: grace and delicacy, both as an attitude and as a silhouette; a celebration of individuality; emotional beauty; the blending and merging of different languages. Style is essential and impalpable. The idea of contemporary humanism leads a creative quest that revolves around the personality of the wearer. Vision, products, retail spaces share the same traits: from the one-of-a-kind Haute Couture creations to Women’s and Men’s ready-to-wear and accessories, from eyewear to fragrances to the boutiques, Valentino is synonymous of elegance, pureness, craftsmanship, uniqueness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005160/en/
Contact information
Media Contacts:
US: Cecilia Fan, ccfan@amazon.com
IT: Federico Filippa, filippa@amazon.it
Maison Valentino Media Contacts:
valentinopressoffice@valentino.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
